SIMPSON v. BAYER PHARMACEUTICAL CORP.

CourtDistrict Court, D. New Jersey
DecidedFebruary 2, 2021
Docket2:05-cv-03895
StatusUnknown

This text of SIMPSON v. BAYER PHARMACEUTICAL CORP. (SIMPSON v. BAYER PHARMACEUTICAL CORP.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
SIMPSON v. BAYER PHARMACEUTICAL CORP., (D.N.J. 2021).

Opinion

Not for Publication

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

UNITED STATES OF AMERICA, ex rel., LAURIE SIMPSON Civil Action No. 05-3895 Plaintiff, v. OPINION & ORDER BAYER A.G., et al. Defendants,

John Michael Vazquez, U.S.D.J. This matter comes before the Court on an appeal from the ruling of Special Master Dennis M. Cavanaugh, U.S.D.J. (Ret.) denying the motion of non-party United States (the “Government”) to shift the costs and expenses that the Centers for Medicare and Medicaid Services (“CMS”) incurred because of Defendants’ subpoena (the “Subpoena”). The Court reviewed the parties’ submissions, D.E. 378 (“Br.”), D.E. 382 (“Opp.”), D.E. 383 (“Reply”) and decided the motion without oral argument pursuant to Fed. R. Civ. P. 78(b) and L. Civ. R. 78.1(b). For the reasons stated below, the Government’s appeal is denied. I. BACKGROUND This case arises under the False Claims Act. See e.g., D.E. 213 ¶ 4; see 31 U.S.C. § 3729 et seq. The Tenth Amended Complaint is the operative pleading. See D.E. 213. Relator seeks to recover for false claims and statements that Defendants allegedly made in connection with their “unlawful marketing, including off-label marketing and payment of kickbacks, . . . to increase the market shares of its prescription drugs Trasylol and Avelox.” See e.g., id. ¶ 9. The Government declined to intervene on February 10, 2010. D.E. 16. Now before the Court is the Government’s appeal of the Special Master’s ruling denying the Government’s motion to shift costs under Fed. R. Civ. P. 45. D.E. 377. On March 13, 2019, Defendants served the Subpoena on CMS. D.E. 363-2. On October 3, 2019, the Government moved to quash or modify the Subpoena as to the portions of document

request numbers one, eight, nine, fourteen, and fifteen. The Government contends that those requests would have required CMS to produce, in effect, “230 million pages of aged Medicare paper records dating from 1996 through 1999, contained in over 91,000 boxes dispersed at several government storage sites around the country that were scheduled for disposal,” (the “aged paper records”). See D.E. 363 at 1; see also D.E. 363-1 (“Klots Decl.”) at 8, ¶ 19. On March 26, 2020, the Special Master granted the Government’s motion to quash the Subpoena. See D.E. 378-12. As to the aged paper records, the Special Master found that Defendants failed to meet their burden “to demonstrate that the boxes containing the aged paper records are relevant.” Id. at 10. The Special Master reasoned that “the vast majority of the [aged paper records] are outside the discovery period germane to this case” because the “[Tenth Amended Complaint] clearly only

alleges that the Causes of Action are based on fraudulent claims for Trasylol on or after August 5, 1999 and fraudulent claims for Avelox on or after July 24, 2000.” Id. at 10. The Special Master concluded that “the boxes containing paper records from 1996, 1997, and 1998 are outside the discovery period and not relevant[.]” Id. at 11. The Special Master also found that Defendants failed to demonstrate that the boxes that could contain aged paper records for Trasylol in 1999 held information that could not be obtained from other sources. Id. Relying on the Government’s declaration, see Klots Decl. at 4-5, ¶¶ 13-14, the Special Master explained that the data contained on the face of the aged paper records was available through the “National Claims History data base at the CMS data center” and that Defendants failed to explain how that database was “inadequate and why the paper records themselves must be provided.” D.E. 378-12 at 11. The Special Master further questioned the relevance of the aged paper records given that they “do not include the information related to payment decisions on the claims.” Id.; see also Klots Decl. at 5 ¶ 14. The Special Master opined that it would be “difficult to ascertain how [Defendants] could ‘learn

whether the Government consistently refuses to pay claims in the mine of run cases based on noncompliance with the two legal requirements at issue’ when payment decisions are not included with the aged paper records.” D.E. 378-12 at 11. The Special Master found that, “at most,” Defendants had argued that the aged paper records might contain “potentially relevant information” to their defense, which did not meet the discovery standard under Fed. R. Civ. P. 26. Id. (internal quotation marks omitted). The Special Master therefore quashed the Subpoena “to the extent it applie[d] to the aged Medicare paper records dating from 1996 through 1999.” Id. at 12. The Special Master also denied Defendants’ motion for reconsideration. D.E. 376. The Government then moved to shift costs under Fed. R. Civ. P. 45 for CMS’s loss of appropriated funds and storage expenses incurred because of its compliance with the Subpoena. D.E. 373 at 8-10; D.E. 374 at 2-7.1 The Government contended that cost shifting was appropriate

under Fed. R. Civ. P. 45(d)(1) and Fed. R. Civ. P. 45(d)(2)(B).

1 It appears that the Government first raised the issue of cost shifting in its opposition to Defendants’ motion to reconsider. See Br. at 12-13; see also D.E. 373 at 8-10; D.E. 374 at 2-7. Defendants objected. See D.E. 377 at 2 (“Bayer argues that an opposition to a motion for reconsideration is not an appropriate forum to raise new cost-shifting issues.”); see also Opp. at 11 n. 5 (arguing the Government’s claim for costs “was forfeited because an opposition to a reconsideration motion is too late . . . to raise new arguments and issues . . . [and because] the Government never gave ‘notice of its intention to seek costs, or conditioned its compliance on reimbursement’ until its opposition to Bayer’s motion for reconsideration.” (citing See P. Schoenfeld Asset Mgmt. LLC v. Cendant Corp., 161 F. Supp. 2d 349, 352 (D.N.J. 2001), Lee v. Va. State Bd. of Elections, No. 3:15CV357, 2016 WL 6915308, at *3 (E.D. Va. Sept. 2, 2016))). However, the Government acknowledges the Special Master did not ultimately rule on this argument, Opp. at 11 n. 5, and Defendants have not appealed the Special Master’s decision not to do so. The Special Master denied the Government’s motion as to Rule 45(d)(2)(B). D.E. 377 at 4. That rule provides as follows: A person commanded to produce documents or tangible things or to permit inspection may serve on the party or attorney designated in the subpoena a written objection . . . . If an objection [to a subpoena] is made, the following rules apply:

(i) At any time, on notice to the commanded person, the serving party may move the court for the district where compliance is required for an order compelling production or inspection.

(ii) These acts may be required only as directed in the order, and the order must protect a person who is neither a party nor a party’s officer from significant expense resulting from compliance.

Fed. R. Civ. P. 45(d)(2)(B).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. United States Gypsum Co.
333 U.S. 364 (Supreme Court, 1948)
Anderson v. City of Bessemer City
470 U.S. 564 (Supreme Court, 1985)
P. Schoenfeld Asset Management LLC v. Cendant Corp.
161 F. Supp. 2d 349 (D. New Jersey, 2001)
McCabe v. Ernst & Young, LLP
221 F.R.D. 423 (D. New York, 2004)
United States v. McGraw-Hill Companies, Inc.
302 F.R.D. 532 (C.D. California, 2014)
Fisher v. Marubeni Cotton Corp.
526 F.2d 1338 (Eighth Circuit, 1975)
Cooper Hospital/University Medical Center v. Sullivan
183 F.R.D. 119 (D. New Jersey, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
SIMPSON v. BAYER PHARMACEUTICAL CORP., Counsel Stack Legal Research, https://law.counselstack.com/opinion/simpson-v-bayer-pharmaceutical-corp-njd-2021.